Janux Therapeutics (JANX) Enterprise Value (2020 - 2025)
Janux Therapeutics (JANX) has disclosed Enterprise Value for 6 consecutive years, with -$966.6 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 5.72% to -$966.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$966.6 million, a 5.72% increase, with the full-year FY2025 number at -$966.6 million, up 5.72% from a year prior.
- Enterprise Value was -$966.6 million for Q4 2025 at Janux Therapeutics, up from -$989.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$303.3 million in Q2 2023 to a low of -$1.0 billion in Q4 2024.
- A 5-year average of -$568.4 million and a median of -$387.5 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 4699.24% in 2021, then rose 14.4% in 2023.
- Janux Therapeutics' Enterprise Value stood at -$375.0 million in 2021, then grew by 12.79% to -$327.0 million in 2022, then dropped by 5.2% to -$344.0 million in 2023, then tumbled by 197.99% to -$1.0 billion in 2024, then rose by 5.72% to -$966.6 million in 2025.
- Per Business Quant, the three most recent readings for JANX's Enterprise Value are -$966.6 million (Q4 2025), -$989.0 million (Q3 2025), and -$996.0 million (Q2 2025).